|
The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients Clinical research trials and The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients. The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients clinical trial. Human subjects frequently get the finest healthcare available for their The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients  The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients
The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients
For Condition: Candidiasis, Oral,HIV Infections
Status: Completed
Sponsor(s): Procter & Gamble Pharmaceuticals ,
Synopsis: To evaluate the safety and effectiveness of Peridex (an oral rinse containing chlorhexidine gluconate) for preventing the occurrence of clinically-evident microbiologically-documented oral candidiasis in HIV-positive patients, who are at risk of the disease based on previous history of candidiasis.
Details:
Eligibility:
Study Type: Interventional, Treatment, Dose Comparison
Minimum Age/Maximum Age: 13 Years/75 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Prior Medication: Allowed within 6 months of study entry: - Treatment for oral candidiasis. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Either history of esophageal candidiasis or current mucocutaneous candidiasis (angular cheilitis). - Allergies to chlorhexidine. - Gross periodontal neglect or need for periodontal treatment within the past two weeks. Concurrent Medication: Excluded: - Systemic or oral topical mucocutaneous antifungal therapy. - Systemic or oral topical corticosteroids. - Antibiotics. - Mouth rinses other than the study drug. Concurrent Treatment: Excluded: - Dental prophylaxis. Patients with the following are excluded: - Complete dentures, full partial dentures, removable dentures which fit poorly, or any prosthetic appliances which cannot be cleaned with sodium hypochlorite. - Allergies to chlorhexidine. - Sensitivity/intolerance to alcohol. - Anterior composite/acrylic restorations with poor marginal adaption. - Gross periodontal neglect or periodontal treatment within the past two weeks. - Inability to comply with the study protocol based on the investigator's discretion. Prior Medication: Excluded within 7 days of study entry: - Systemic or oral topical mucocutaneous antifungal therapy. - Antibiotics. - Daily use of mouth rinses. - Excluded within 1 month of study entry: - Systemic or oral topical corticosteroids. Prior Treatment: Excluded within 2 weeks of starting study drug: - Dental prophylaxis or periodontal treatment. Patients must be: - HIV positive. - Previously experienced at least one episode of clinically diagnosed oral candidiasis but currently free of clinical signs of oral candidiasis. - Willing to sign informed consent. - Willing to complete a medical history.
Total Enrollment:
Location and Contact Information:
Ohio State Univ Hosp Clinic
Columbus, Ohio, 432101228
United States
Bering Dental Clinic
Houston, Texas, 77006
United States
Dental Research Institute / UCLA Med Ctr
Los Angeles, California, 900951762
United States
UCSF / Stomatology Clinical Ctr
San Francisco, California, 94143
United States
Hermann Hosp / Univ Texas Health Science Ctr
Houston, Texas, 77030
United States
Additional Information:
Study ID Numbers: 050A; CC-220
Study Start Date:
Record last reviewed: November 1993
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002431
Other Hiv Infections Studies:
1. The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
2. Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV
3. A Study of Nevirapine to Prevent HIV Transmission from Mothers to Their Babies
4. A Study of Isoprinosine in Patients with Severe AIDS
5. A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy
Related Studies:
Other HIV Infections Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients
|
|
|
|
|
|
|
|
